Pharmacyte Biotech Inc (PMCB) 0.0880 $PMCB
PharmaCyte Biotech Retains Industry Expert to Monitor Short Sellers and Market Makers
GlobeNewswire - Thu Oct 01, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell in a Box, announced today that BUYINS.NET, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Pharmacyte Biotech after releasing the latest short sale data through September 29, 2015. BUYINS.NET will monitor the market makers of PharmaCyte Biotech's stock daily for compliance with fair market-making requirements.
BUYINS.NET Issues PharmaCyte Biotech (PMCB) SqueezeTrigger Report
M2 - Thu Oct 01, 7:39AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Pharmacyte Biotech (OTC: PMCB) after releasing the latest short sale data through September 29, 2015. The total aggregate number of shares shorted since August 2009 is approximately 916 million shares. Approximately 34.76% of daily trading volume is short selling. The SqueezeTrigger price for all PMCB shares shorted is $.1838. A short squeeze is expected to begin when the stock closes above the $.1838 SqueezeTrigger price.
PharmaCyte Biotech Moves Closer to Revealing Plan to Address Unmet Medical Need in Phase 2b Clinical Trial
Marketwired - Wed Sep 30, 8:30AM CDT
Cancer is the world's second most common cause of death, not too far behind heart disease. And, although no form of cancer is "good," pancreatic cancer is perhaps the least treatable and most discouraging, taking the lives of more than 86% of its victims within five years of being diagnosed. PharmaCyte Biotech Inc. (OTCQB: PMCB) is developing a treatment regimen that could significantly address this unmet medical need.
PharmaCyte Biotech's Encapsulation Technology Could Address Unmet Medical Need
GlobeNewswire - Mon Sep 28, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, released today the second in a series of articles that will serve to educate the public on its technology and how it is used in the treatment of advanced pancreatic cancer. This latest article, written by Dr. Matthias Lohr of the famed Karolinska Institute in Stockholm, Sweden, and the Chairman of PharmaCyte Biotech's Scientific Advisory Board, discusses the unmet clinical need of a large group of patients suffering from locally advanced pancreatic cancer.
SHAREHOLDER UPDATE: PharmaCyte Biotech Starts the Path to Phase II Clinicals - Small Cap Street
PR Newswire - Mon Sep 28, 7:20AM CDT
Small Cap Street issues due diligence report. PharmaCyte Biotech, Inc. (OTCQB: PMCB) shares ended the week at $.0795 up 10.42%. Share volume was at near average levels at 2 million shares.
PharmaCyte Biotech Hires Industry-Leading Firm to Assist With Investigational New Drug Application
GlobeNewswire - Fri Sep 25, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes announced today that it has contracted with Chamow & Associates, located in the San Francisco Bay Area, to assist with the Chemistry, Manufacturing and Control (CMC) regulatory requirements for its Phase 2b clinical trial in advanced pancreatic cancer. CMC information is a crucial part of the Investigational New Drug (IND) application that PharmaCyte Biotech will be submitting to the regulatory authorities. PharmaCyte Biotech will leverage the expertise of Chamow & Associates in this process.
PharmaCyte Biotech Discusses Pancreatic Cancer Treatment for Upcoming Phase 2b Human Clinical Trial
GlobeNewswire - Tue Sep 22, 9:42AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, released today the first in a series of articles that will serve to educate the public on its technology and how it is used in the treatment of advanced pancreatic cancer. These articles will be written by doctors, scientists and oncologists who are associated with PharmaCyte Biotech's upcoming Phase 2b clinical trial. This first educational piece is authored by PharmaCyte Biotech's Chief Operating Officer, Dr. Gerald W. Crabtree, with the goal of explaining PharmaCyte Biotech's treatment.
PharmaCyte Biotech Discusses Major Milestones Ahead of Phase 2b Clinical Trial in Pancreatic Cancer
GlobeNewswire - Tue Sep 15, 8:30AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, discussed today some of the major "milestone" tasks that must be completed to begin its Phase 2b clinical trial in pancreatic cancer. The trial will test the effectiveness and safety of PharmaCyte Biotech's pancreatic cancer treatment. This treatment consists of the combination of microcapsules with genetically modified live cells in combination with low doses of the chemotherapy drug ifosfamide. These encapsulated live cells are placed as close to a cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the patient's cancer.
PharmaCyte Biotech Begins Phase 2b Clinical Trial Push With Imaging Endpoints Contract for Radiological Imaging
GlobeNewswire - Wed Sep 09, 8:30AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that it has contracted with Imaging Endpoints in Scottsdale, Arizona, to perform radiologic imaging that will be required for PharmaCyte Biotech's Phase 2b clinical trial in pancreatic cancer. This is the first in a series of announcements that PharmaCyte will release related to the company's upcoming Phase 2b clinical trial, including a full layout of the dramatically improved clinical trial design. The trial will test the effectiveness of PharmaCyte Biotech's pancreatic cancer treatment (the combination of microcapsules produced using the Cell-in-a-Box technology and low doses of the anticancer drug ifosfamide) in patients with this disease.
PharmaCyte Biotech Announces Successful Completion of Interim Audit of GMP Facility for the Production of Cell-in-a-Box for Clinical Trials
GlobeNewswire - Tue Aug 25, 8:38AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, provided an update on the progress of completing the compliance process for Austrianova's cGMP (current Good Manufacturing Practices-compliant) facility in the Thai Science Park in Bangkok, Thailand. This is the facility that will encapsulate genetically modified human cells in the Cell-in-a-Box capsules PharmaCyte Biotech will use in its clinical trials in cancer and diabetes.
PharmaCyte Biotech's Scientific Advisory Board Members Co-Author Major Review on Pancreatic Cancer
GlobeNewswire - Wed Aug 19, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Dr. Matthias Lohr, the Chairman of PharmaCyte Biotech's Scientific Advisory Board, and Dr. Manuel Hidalgo, a recently appointed member of the Board, have joined other oncologists from Spain, Italy, Germany, the U.K. and Belgium in co-authoring a major review article on pancreatic cancer that was recently published in the prestigious scientific journal, Pancreatology. The title of the review article is "Addressing the Challenges of Pancreatic Cancer: Future Directions for Improving Outcomes." The review article can be viewed in its entirety at http://www.pancreatology.net/article/S1424-39...0997-1/pdf.
Small Cap Street Discovers Key Due Diligence on PharmaCyte Biotech
PR Newswire - Tue Aug 18, 7:45AM CDT
Small Cap Street locates due diligence. PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, recently updated its shareholders of the progress of cGMP facility for the production of Cell-in-a-Box for clinical trials. Our due diligence has uncovered some interesting information that current and potential shareholders may want to read:
PharmaCyte Biotech Has Only Scratched the Surface With Its Cell-in-a-Box(R) Technology
Marketwired - Mon Aug 17, 8:01AM CDT
PharmaCyte Biotech Inc. (OTCQB: PMCB) has made a name for itself with the company's potentially game-changing pancreatic cancer treatment, and also as the name behind what could arguably be seen as a cure for type 1 diabetes. What's been largely unsaid about PharmaCyte Biotech, however, is that the same underlying technology behind its Phase 2b pancreatic cancer trial and its preclinical work in the field of type 1 diabetes is a technology with almost limitless applications within the world of medicine.
PharmaCyte Biotech Updates Progress of cGMP Facility for the Production of Cell-in-a-Box for Clinical Trials
GlobeNewswire - Thu Aug 06, 8:30AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced an update on the progress of completing the certification of Austrianova's cGMP (current Good Manufacturing Practices-compliant) facility in the Thai Science Park in Bangkok, Thailand. This is the facility that will encapsulate genetically modified human cells in the Cell-in-a-Box capsules PharmaCyte Biotech will use in its clinical trials in both cancer and diabetes.
Artificial Pancreas - Pipeline Review 2015 Featuring Profiles of 35 Key Companies/Institutions
M2 - Wed Aug 05, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/42bxxs/artificial) has announced the addition of the "Artificial Pancreas - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Artificial Pancreas pipeline products. Scope - Extensive coverage of the Artificial Pancreas products under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Artificial Pancreas and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Products under Development 4 Artificial Pancreas - Pipeline Products under Development by Companies 5 Artificial Pancreas Companies and Product Overview 6 Artificial Pancreas - Recent Developments 7 Appendix Companies Mentioned - Advanced Biosensors-Ohio, Llc - Animas Corporation - Beta-O2 Technologies Ltd. - Bigfoot Biomedical, Inc. - BioTex, Inc. - Boston University - Cerco Medical - Converge Biotech, Inc. - Covalor Medical, LLC - De Montfort University - Defymed - Diabeloop - Dose Safety Inc. - Imperial College London - Inreda Diabetic BV - Kencak LLC - Medtronic plc - Miromatrix Medical Inc. - Pacific Diabetes Technologies, Inc. - Pancreum, LLC - PharmaCyte Biotech, Inc. - Rensselaer Polytechnic Institute - Schneider Children's Medical Center of Israel - TecMed, Inc. - The University of Newcastle - Ultradian Diagnostics LLC - Universidad Autonoma de Madrid - Universitat Politecnica de Valencia - University of California, San Francisco - University of California, Santa Barbara - University of Cambridge - University of Florida - University of Virginia - ViaCyte, Inc. - XERIS Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/42bxxs/artificial
MDT: 71.13 (+2.73)
Chardan Releases Industry Report Covering PharmaCyte Biotech
GlobeNewswire - Tue Aug 04, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Chardan Capital Markets LLC, a privately held full service global investment bank specializing in micro, small and mid-cap companies, issued an Industry Update featuring PharmaCyte Biotech. The report can be viewed at www.PharmaCyte.com/reports.
PharmaCyte Biotech's Improved Technology Attracting World Class Oncologists
Marketwired - Thu Jul 30, 8:02AM CDT
PharmaCyte Biotech (OTCQB: PMCB) is a small international biotechnology firm, but you wouldn't know it by the company it keeps. How does PharmaCyte keep landing such world-renowned oncologists? Well, we think the answer is simple -- proven technology that has only gotten much better over time! The latest name to join PharmaCyte is Dr. Manuel Hidalgo, a renowned clinical and laboratory investigator in both pancreatic cancer and other abdominal cancers. He was recently named to the company's Scientific Advisory Board (SAB), and his appointment prompted a deeper look into the technology and the names involved with it.
PharmaCyte Biotech is Tackling Cancer and Diabetes with Cell In A Box
PRWeb - Thu Jul 30, 2:04AM CDT
"PharmaCyte Biotech" was featured on NewsWatch as part of its monthly Biz Report, which takes a look small, medium, and large businesses making an impact in their industry. Susan Bridges, a reporter for NewsWatch and a business expert, conducted the business review and shared with viewers how this is a clinical stage biotechnology company that focuses on developing treatments for both cancer and diabetes based on a revolutionary live-cell encapsulation technology
Celgene May Also Want to Take Notice of PharmaCyte Biotech
Marketwired - Fri Jul 24, 8:00AM CDT
A recent deal between Celgene and Juno Therapeutics is just a microcosm of the mindset that may ultimately drive a similar deal between it -- or a competitor -- and PharmaCyte Biotech (OTCQB: PMCB).
JUNO: 43.09 (+2.17), CELGZ: 1.69 (+0.02)
PharmaCyte Biotech Begins Second Follow-Up Study on Ascites
GlobeNewswire - Thu Jul 23, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that its follow-up study on ascites began this week. That study is being conducted by Translational Drug Development (TD2) to determine the effectiveness of PharmaCyte Biotech's pancreatic cancer treatment on the rate of accumulation of malignant ascites fluid in patients with pancreatic cancer and other abdominal tumors.
PharmaCyte Biotech Retains Industry Expert to Monitor Short Sellers and Market Makers
GlobeNewswire - Thu Oct 01, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell in a Box, announced today that BUYINS.NET, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Pharmacyte Biotech after releasing the latest short sale data through September 29, 2015. BUYINS.NET will monitor the market makers of PharmaCyte Biotech's stock daily for compliance with fair market-making requirements. BUYINS.NET Issues PharmaCyte Biotech (PMCB) SqueezeTrigger Report
M2 - Thu Oct 01, 7:39AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Pharmacyte Biotech (OTC: PMCB) after releasing the latest short sale data through September 29, 2015. The total aggregate number of shares shorted since August 2009 is approximately 916 million shares. Approximately 34.76% of daily trading volume is short selling. The SqueezeTrigger price for all PMCB shares shorted is $.1838. A short squeeze is expected to begin when the stock closes above the $.1838 SqueezeTrigger price.
PharmaCyte Biotech Moves Closer to Revealing Plan to Address Unmet Medical Need in Phase 2b Clinical Trial
Marketwired - Wed Sep 30, 8:30AM CDT
Cancer is the world's second most common cause of death, not too far behind heart disease. And, although no form of cancer is "good," pancreatic cancer is perhaps the least treatable and most discouraging, taking the lives of more than 86% of its victims within five years of being diagnosed. PharmaCyte Biotech Inc. (OTCQB: PMCB) is developing a treatment regimen that could significantly address this unmet medical need.
PharmaCyte Biotech's Encapsulation Technology Could Address Unmet Medical Need
GlobeNewswire - Mon Sep 28, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, released today the second in a series of articles that will serve to educate the public on its technology and how it is used in the treatment of advanced pancreatic cancer. This latest article, written by Dr. Matthias Lohr of the famed Karolinska Institute in Stockholm, Sweden, and the Chairman of PharmaCyte Biotech's Scientific Advisory Board, discusses the unmet clinical need of a large group of patients suffering from locally advanced pancreatic cancer. SHAREHOLDER UPDATE: PharmaCyte Biotech Starts the Path to Phase II Clinicals - Small Cap Street
PR Newswire - Mon Sep 28, 7:20AM CDT
Small Cap Street issues due diligence report. PharmaCyte Biotech, Inc. (OTCQB: PMCB) shares ended the week at $.0795 up 10.42%. Share volume was at near average levels at 2 million shares.
PharmaCyte Biotech Hires Industry-Leading Firm to Assist With Investigational New Drug Application
GlobeNewswire - Fri Sep 25, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes announced today that it has contracted with Chamow & Associates, located in the San Francisco Bay Area, to assist with the Chemistry, Manufacturing and Control (CMC) regulatory requirements for its Phase 2b clinical trial in advanced pancreatic cancer. CMC information is a crucial part of the Investigational New Drug (IND) application that PharmaCyte Biotech will be submitting to the regulatory authorities. PharmaCyte Biotech will leverage the expertise of Chamow & Associates in this process. PharmaCyte Biotech Discusses Pancreatic Cancer Treatment for Upcoming Phase 2b Human Clinical Trial
GlobeNewswire - Tue Sep 22, 9:42AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, released today the first in a series of articles that will serve to educate the public on its technology and how it is used in the treatment of advanced pancreatic cancer. These articles will be written by doctors, scientists and oncologists who are associated with PharmaCyte Biotech's upcoming Phase 2b clinical trial. This first educational piece is authored by PharmaCyte Biotech's Chief Operating Officer, Dr. Gerald W. Crabtree, with the goal of explaining PharmaCyte Biotech's treatment. PharmaCyte Biotech Discusses Major Milestones Ahead of Phase 2b Clinical Trial in Pancreatic Cancer
GlobeNewswire - Tue Sep 15, 8:30AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, discussed today some of the major "milestone" tasks that must be completed to begin its Phase 2b clinical trial in pancreatic cancer. The trial will test the effectiveness and safety of PharmaCyte Biotech's pancreatic cancer treatment. This treatment consists of the combination of microcapsules with genetically modified live cells in combination with low doses of the chemotherapy drug ifosfamide. These encapsulated live cells are placed as close to a cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the patient's cancer. PharmaCyte Biotech Begins Phase 2b Clinical Trial Push With Imaging Endpoints Contract for Radiological Imaging
GlobeNewswire - Wed Sep 09, 8:30AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that it has contracted with Imaging Endpoints in Scottsdale, Arizona, to perform radiologic imaging that will be required for PharmaCyte Biotech's Phase 2b clinical trial in pancreatic cancer. This is the first in a series of announcements that PharmaCyte will release related to the company's upcoming Phase 2b clinical trial, including a full layout of the dramatically improved clinical trial design. The trial will test the effectiveness of PharmaCyte Biotech's pancreatic cancer treatment (the combination of microcapsules produced using the Cell-in-a-Box technology and low doses of the anticancer drug ifosfamide) in patients with this disease. PharmaCyte Biotech Announces Successful Completion of Interim Audit of GMP Facility for the Production of Cell-in-a-Box for Clinical Trials
GlobeNewswire - Tue Aug 25, 8:38AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, provided an update on the progress of completing the compliance process for Austrianova's cGMP (current Good Manufacturing Practices-compliant) facility in the Thai Science Park in Bangkok, Thailand. This is the facility that will encapsulate genetically modified human cells in the Cell-in-a-Box capsules PharmaCyte Biotech will use in its clinical trials in cancer and diabetes. PharmaCyte Biotech's Scientific Advisory Board Members Co-Author Major Review on Pancreatic Cancer
GlobeNewswire - Wed Aug 19, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Dr. Matthias Lohr, the Chairman of PharmaCyte Biotech's Scientific Advisory Board, and Dr. Manuel Hidalgo, a recently appointed member of the Board, have joined other oncologists from Spain, Italy, Germany, the U.K. and Belgium in co-authoring a major review article on pancreatic cancer that was recently published in the prestigious scientific journal, Pancreatology. The title of the review article is "Addressing the Challenges of Pancreatic Cancer: Future Directions for Improving Outcomes." The review article can be viewed in its entirety at http://www.pancreatology.net/article/S1424-39...0997-1/pdf. Small Cap Street Discovers Key Due Diligence on PharmaCyte Biotech
PR Newswire - Tue Aug 18, 7:45AM CDT
Small Cap Street locates due diligence. PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, recently updated its shareholders of the progress of cGMP facility for the production of Cell-in-a-Box for clinical trials. Our due diligence has uncovered some interesting information that current and potential shareholders may want to read:
PharmaCyte Biotech Has Only Scratched the Surface With Its Cell-in-a-Box(R) Technology
Marketwired - Mon Aug 17, 8:01AM CDT
PharmaCyte Biotech Inc. (OTCQB: PMCB) has made a name for itself with the company's potentially game-changing pancreatic cancer treatment, and also as the name behind what could arguably be seen as a cure for type 1 diabetes. What's been largely unsaid about PharmaCyte Biotech, however, is that the same underlying technology behind its Phase 2b pancreatic cancer trial and its preclinical work in the field of type 1 diabetes is a technology with almost limitless applications within the world of medicine.
PharmaCyte Biotech Updates Progress of cGMP Facility for the Production of Cell-in-a-Box for Clinical Trials
GlobeNewswire - Thu Aug 06, 8:30AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced an update on the progress of completing the certification of Austrianova's cGMP (current Good Manufacturing Practices-compliant) facility in the Thai Science Park in Bangkok, Thailand. This is the facility that will encapsulate genetically modified human cells in the Cell-in-a-Box capsules PharmaCyte Biotech will use in its clinical trials in both cancer and diabetes. Artificial Pancreas - Pipeline Review 2015 Featuring Profiles of 35 Key Companies/Institutions
M2 - Wed Aug 05, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/42bxxs/artificial) has announced the addition of the "Artificial Pancreas - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Artificial Pancreas pipeline products. Scope - Extensive coverage of the Artificial Pancreas products under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Artificial Pancreas and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Products under Development 4 Artificial Pancreas - Pipeline Products under Development by Companies 5 Artificial Pancreas Companies and Product Overview 6 Artificial Pancreas - Recent Developments 7 Appendix Companies Mentioned - Advanced Biosensors-Ohio, Llc - Animas Corporation - Beta-O2 Technologies Ltd. - Bigfoot Biomedical, Inc. - BioTex, Inc. - Boston University - Cerco Medical - Converge Biotech, Inc. - Covalor Medical, LLC - De Montfort University - Defymed - Diabeloop - Dose Safety Inc. - Imperial College London - Inreda Diabetic BV - Kencak LLC - Medtronic plc - Miromatrix Medical Inc. - Pacific Diabetes Technologies, Inc. - Pancreum, LLC - PharmaCyte Biotech, Inc. - Rensselaer Polytechnic Institute - Schneider Children's Medical Center of Israel - TecMed, Inc. - The University of Newcastle - Ultradian Diagnostics LLC - Universidad Autonoma de Madrid - Universitat Politecnica de Valencia - University of California, San Francisco - University of California, Santa Barbara - University of Cambridge - University of Florida - University of Virginia - ViaCyte, Inc. - XERIS Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/42bxxs/artificial
MDT: 71.13 (+2.73)
Chardan Releases Industry Report Covering PharmaCyte Biotech
GlobeNewswire - Tue Aug 04, 8:00AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that Chardan Capital Markets LLC, a privately held full service global investment bank specializing in micro, small and mid-cap companies, issued an Industry Update featuring PharmaCyte Biotech. The report can be viewed at www.PharmaCyte.com/reports. PharmaCyte Biotech's Improved Technology Attracting World Class Oncologists
Marketwired - Thu Jul 30, 8:02AM CDT
PharmaCyte Biotech (OTCQB: PMCB) is a small international biotechnology firm, but you wouldn't know it by the company it keeps. How does PharmaCyte keep landing such world-renowned oncologists? Well, we think the answer is simple -- proven technology that has only gotten much better over time! The latest name to join PharmaCyte is Dr. Manuel Hidalgo, a renowned clinical and laboratory investigator in both pancreatic cancer and other abdominal cancers. He was recently named to the company's Scientific Advisory Board (SAB), and his appointment prompted a deeper look into the technology and the names involved with it.
PharmaCyte Biotech is Tackling Cancer and Diabetes with Cell In A Box
PRWeb - Thu Jul 30, 2:04AM CDT
"PharmaCyte Biotech" was featured on NewsWatch as part of its monthly Biz Report, which takes a look small, medium, and large businesses making an impact in their industry. Susan Bridges, a reporter for NewsWatch and a business expert, conducted the business review and shared with viewers how this is a clinical stage biotechnology company that focuses on developing treatments for both cancer and diabetes based on a revolutionary live-cell encapsulation technology
Celgene May Also Want to Take Notice of PharmaCyte Biotech
Marketwired - Fri Jul 24, 8:00AM CDT
A recent deal between Celgene and Juno Therapeutics is just a microcosm of the mindset that may ultimately drive a similar deal between it -- or a competitor -- and PharmaCyte Biotech (OTCQB: PMCB).
JUNO: 43.09 (+2.17), CELGZ: 1.69 (+0.02)
PharmaCyte Biotech Begins Second Follow-Up Study on Ascites
GlobeNewswire - Thu Jul 23, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that its follow-up study on ascites began this week. That study is being conducted by Translational Drug Development (TD2) to determine the effectiveness of PharmaCyte Biotech's pancreatic cancer treatment on the rate of accumulation of malignant ascites fluid in patients with pancreatic cancer and other abdominal tumors. 
